Radiopharm Theranostics’ (RADX) Buy Rating Reiterated at B. Riley

B. Riley reiterated their buy rating on shares of Radiopharm Theranostics (NASDAQ:RADX) in a research note published on Tuesday,Benzinga reports. B. Riley currently has a $16.00 price target on the stock, up from their previous price target of $13.00.

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Radiopharm Theranostics in a research note on Wednesday, October 8th. Two research analysts have rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Buy” and a consensus price target of $15.33.

Radiopharm Theranostics Stock Up 2.8%

Radiopharm Theranostics stock opened at $5.49 on Tuesday. The company has a fifty day simple moving average of $5.22 and a 200-day simple moving average of $5.25. Radiopharm Theranostics has a 52-week low of $3.50 and a 52-week high of $16.25.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Radiopharm Theranostics stock. PNC Financial Services Group Inc. acquired a new position in Radiopharm Theranostics Limited – Sponsored ADR (NASDAQ:RADX) in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 8,000 shares of the company’s stock, valued at approximately $37,000. PNC Financial Services Group Inc. owned 0.10% of Radiopharm Theranostics as of its most recent filing with the Securities & Exchange Commission.

Radiopharm Theranostics Company Profile

Radiopharm Theranostics Ltd. operates as a pre-clinical and clinical research company. It focuses on the development of radiopharmaceutical products for diagnostic and therapeutic uses in areas of high unmet medical need. The company is headquartered Carlton, Australia.